论文部分内容阅读
The natural BH3-mimetic (-)-gossypol is currently undergoing Phase Ⅱ-Ⅲ clinical trials forhuman prostate cancer and showing promising efficacy.Here we show that suppression of Akt/mTOR pathway by NVP-BEZ235 significantly enhanced (-)-gossypol-induced eytotoxicityin androgen-independent prostate cancer cells (AI-PC cells) in vitro and in vivo.